Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

  • 17k

    Total downloads

  • 58k

    Total views and downloads

About this Research Topic

Submission closed

Background

The incredible power of the immune system to control or eliminate neoplasias has been made evident by the success of immune checkpoint inhibitors (ICI). While inhibitory checkpoint receptors are critical for the maintenance of hemostasis under physiological conditions, dysregulation in the tumor microenvironment perturbs the role of these molecules with the promotion of exhausted cytotoxic cells, that is cytotoxic cells that no longer are able to control tumors. ICI leverages these targets to redirect cytotoxic responses and neutralize the suppressive tumor microenvironment. However, not all tumor types or patients respond to these therapies. Great interest continues to be focussed on first-generation ICI therapy (PD-1/PD-L1 and CTLA-4) but the potential for other targets and ligands remains vast.

To move beyond these original targets one must focus on emerging immunosuppressive molecules in exhausted cells, such as TIGIT, Tim-3, LAG-3, VISTA, BTLA, CD161, GITR, NKG2A, A2AR, the yet unknown receptors of B7H3, B7H4, and the enzymes IDO1, CD39, CD73, and CD38. These receptors, and/or their ligands may be considered targets in combination with traditional ICI, as stand-alone objectives, or as biomarkers to select patient populations most likely to respond to ICI therapy. The flip side of the coin is receptors that selectively activate cytotoxic cells, such as OX40, 4-1BB, GITR, ICOS, NKG2D, CD6, CD2, CD70/CD27, IL2R, NKp46, CD16, CD40, TLR3/9, and their agonists is relatively unexplored in comparison with the inhibitory checkpoint pathways. Just as inhibition of an inhibitory pathway has shown incredible promise in re-invigorating exhausted cells, the addition of agonistic activating signals via the above receptors shows great potential for reactivation of anti-tumor immune responses.

Putting these two ideas together, that is that both next-generation inhibitory targets and underutilized co-stimulatory activating receptors may be present on the aforementioned exhausted cells, opens the door to novel designs for multi-specific redirectors or functionalized CAR-T or NK cells.

Recently the role of MSI as a selective marker in combination with PD-1 blockade has been made very evident. This leads to the question: what else “upstream” might control the expression of biomarkers such as PD-L1? Of a tumor turning from “cold” to “hot?” What role do molecules such as TOX have in controlling the expression of traditional ICI targets such as PD-1 and CTLA-4?

With thousands of clinical trials focused on the classical checkpoint targets currently in play, the fact remains that this very promising technology does not work for all cancers, nor all patients within a given cancer classification. Here, we would like to present articles to readers seeking new checkpoint targets, novel technologies utilizing checkpoints, or biomarkers that can optimize patient selection for future studies.

We welcome the submission of Original Research, Review, and Mini-Review articles covering the following topics:
1. Molecular mechanisms underlying the regulation of checkpoint ligand expression in the tumor microenvironment and/or cancer cells.
2. Identification of novel checkpoint interactions between cancer and immune cells.
3. Use of agonists of co-stimulatory checkpoint receptors to selectively activate cytotoxic cell populations.
4. Identification of anti-tumor checkpoint targets on innate cells, such as NK, NKT, ILC, and MAIT cells.
5. Combination of ICI with targeted cancer treatments or emerging technologies to synergize therapeutic results.
6. Application of multiple checkpoint targets to improve selectivity and specificity in re-directing T cells or in CAR strategies
7. Identification of unique biomarkers or biomarker combinations to predict response to checkpoint blockade.

Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.

Keywords: combined checkpoint therapies, ICI, engagers, redirecting T cells, biomarkers, CAR, innate, NK, agonist, inflammation, phagocytosis

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

    In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.

Participating Journals

Impact

  • 58kTopic views
  • 40kArticle views
  • 17kArticle downloads
View impact